Abstract: The invention provides a method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising detecting antibodies to BORIS in a sample obtained from the mammal. The invention also provides BORIS polypeptides as well as compositions and kits comprising the BORIS polypeptides and methods of using the same. The invention further provides a method of inducing an immune response in a mammal using BORIS polypeptides.

Abstract: The invention provides diagnostic, prognostic, and therapeutic uses for detecting COP1 overexpression in a variety of cancers. The methods and uses can further include detecting p53 expression. The invention also provides reagents and kits for use in screening for test compounds that interfere with COP1 and p53 binding.

Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Abstract: Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed.

Abstract: A method for the differentiation of inflammatory bowel disease (IBD) from irritable bowel disease (IBS) followed by distinguishing ulcerative colitis and Crohn's disease from other gastrointestinal illnesses. This highly differential method first uses the presence of elevated lactoferrin as a marker of intestinal inflammation to differentiate IBD from IBS. Patients suspected of IBD are then analyzed for fecal anti-Saccharomyces cerevisiae antibodies (ASCA) as an indicator of Crohn's disease and fecal anti-neutrophil cytoplasmic antibodies (ANCA) as an indicator of ulcerative colitis. IBD patients are further monitored for intestinal inflammation using fecal lactoferrin to evaluate the effectiveness of medical therapy and to predict relapse. The apparatus comprises either a qualitative enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobins for the measurement of total endogenous lactoferrin, ASCA and ANCA in human feces.

Abstract: This invention provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and/or epitopes of autoantigens, allergens, graft antigens, etc. The antibody specificity profile is determined through the binding of patient samples comprising antibodies to the arrays. The array can comprises antigens and epitopes. The invention also provides the means and methods for determining antigen or epitope specificity profiles that can be used in the development of either generic and individualized diagnosis and treatment for immune related diseases, including autoimmune disease, allergy and graft rejection.

Abstract: The present invention relates to a method for automatically determining the endogenous thrombin potential of a blood or plasma sample.

Abstract: The present invention relates to the assessment of lung cancer. It discloses the use of protein NNMT in the assessment of lung cancer. It also relates to a method for assessing lung cancer by measuring NNMT in vitro in a liquid sample derived from an individual. Measurement of NNMT can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.

Abstract: The present invention provides methods for the detection of biliverdin in birds (avian species) and reptiles.

Abstract: There is provided a method of separating free-astaxanthin selectively from green algae and, more particularly, to a method of separating free-astaxanthin selectively from Haematococcus pluvialis, the method comprising: mixing a cell culture containing Haematococcus pluvialis with an alkanic solvent and stirring, thereby obtaining an alkanic solvent extract containing astaxanthin material including free-astaxanthin and astaxanthin ester (step 1); and mixing the alkanic solvent extract with an alcohol and stirring, thereby obtaining an alcoholic extract containing free-astaxanthin (step 2).

Abstract: Process for the preparation of a hydrolysed casein product comprising tripeptides VPP, IPP and/or LPP, wherein a substrate comprising casein or casein fragments is subjected to enzyme treatment wherein the enzyme is derived from Aspergillus, wherein the enzyme concentration is 2-10 wt. % based on casein and that the enzyme has a high proteolytic activity.

Abstract: Lantibiotics are synthesized on ribosomes as prepeptides and post-translationally modified to a mature form. These modifications include dehydrations and cyclizations. Compounds and related methods of generating compounds, modified by dehydration, cyclization, or dehydration and cyclization, are disclosed. The disclosure includes in vitro approaches to effecting dehydration and cyclization leading to production of biologically active compounds such as lantibiotics and variants thereof. Synthetic variants and methods including combinatorial approaches for generating diverse lantibiotics and other compounds are disclosed. The invention has broad potential for applications including food, agricultural, and medical industries.

Abstract: The invention relates to a method for the enzymatic elimination of the N-acyl side chain from lipopeptides to form the corresponding nucleus, wherein the lipopeptide is prepared by fermentation, the lipopeptide being bound to the cells of the biomass, and the biomass is removed with the adhering lipopeptide, the biomass with the adhering lipopeptide is resuspended in an aqueous system, a suitable deacylase is added in dissolved or solid form to the suspension of the biomass, and the corresponding nucleus is formed, and the nucleus is optionally isolated and purified, wherein the lipopeptide obtained by fermentation is reacted after the end of the fermentation as cell-bound biomass without further purification directly with a deacylase, whereby the N-acyl chain linked via an amide linkage is eliminated.

Abstract: A method and composition for tRNA synthetases that activate and aminoacylate nonstandard and noncognate amino acids to tRNA adaptor molecules is described that can be used to generate custom designed protein products for uses in medicinal, therapeutic, diagnostic, biotechnology, engineering, and spectroscopy applications. Some tRNA synthetases naturally misactivate and misaminoacylate noncognate amino acids. Many of these tRNA synthetases, including but not limited to leucyl-, isoleucyl-, and valyl-tRNA synthetases, have evolved proofreading and editing mechanisms to correct these mistakes. Inactivation of the enzyme's editing activity allows and facilitates production and accumulation of tRNAs that are misaminoacylated with nonstandard and noncognate amino acids. These misaminoacylated tRNAs can be used to introduce novel amino acids into proteins.

Abstract: The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.

Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.

Abstract: The present invention relates to an expression vector, comprising a polynucleotide encoding a fusion protein comprising the signal sequence of the gac gene of Pseudomonas diminuta and a polypeptide of interest, a prokaryotic host cell transformed with such an expression vector and a process for production of a polypeptide of interest using said host cell and said expression vector.

Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.

Abstract: The present invention relates to a method of protein synthesis and, more particularly, to a method of effective protein synthesis by regulating the expression of a protein in a host cell, wherein said host cell is transformed with an expression vector comprising a promoter as well as a DNA fragment for a gene that encodes a desired protein, wherein said promoter has an inductive activity for transcription during the resting stage of cell growth and also the induction of said protein expression can be controlled by varying culturing conditions.

Abstract: Described are methods for identifying, selecting, and obtaining mammalian cells capable of producing proteinaceous molecules having predetermined post-translational modifications, wherein the post-translational modifications are brought about by the mammalian cell in which the proteinaceous molecule is expressed. Preferably, the predetermined post-translational modifications include glycosylation. Also described are methods for obtaining and producing proteinaceous molecules, using mammalian cells obtainable by a method of the present invention. Preferably, the proteinaceous molecules include erythropoietin (EPO), since EPO's effect depends heavily on its glycosylation pattern. Mammalian cells that have been obtained on the basis of their ability to produce proteins and/or post-translational modifications that are indicative for a predetermined post-translational modification that is desired are also provided.

Abstract: The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.

Abstract: An isolated protein complex is provided which includes a growth factor, growth factor binding protein and vitronectin. Preferably, the isolated protein complex includes an insulin-like growth factor-I, insulin-like growth factor binding protein-3 or insulin-like growth factor binding protein-5 and vitronectin. Also provided are methods of modulating cell proliferation and/or migration by administering said protein complex for the purposes of wound healing, skin repair and tissue replacement therapy. Conversely, by using agents that disrupt growth factor protein complexes formed in vivo, growth factor-driven cell proliferation and/or migration may be suppressed such as for the purposes of treating cancers, psoriasis, atherosclerosis and wounds prone to hypertrophic scarring.

Abstract: Antigenic and immunogenic determinants of Merozoite surface protein 3 (MSP3). Antigenicity and functional assays identified a 68-amino acid conserved domain of MSP3 as a target of biologically active antibodies. A peptide comprising amino acid residues 184-251 of SEQ ID NO: 2, may also be employed as may peptides consisting of different combinations of the MSP3 a, b, c, d, e and f peptides. Particular non-overlapping or overlapping segments of MSP3 a, b, c, d, e and f peptides may also be used. The various overlapping segments and nonoverlapping segments among the different MSP3 peptides are shown in FIG. 6. MSP3 determinants include targets of antibody-dependent cellular inhibition (ADCI) which is a protective mechanism against Plasmodium falciparum malaria. Six overlapping peptides were derived from the C-terminal end of the MSP3 polypeptide. Each of these peptides defined at least 1 non-crossreactive B cell epitope and contained T helper epitopes.

Abstract: Methods of using beta-alanine/pyruvate aminotransferase to produce 3-hydroxypropionic acid and derivatives thereof, from beta-alanine, are disclosed. Cells and recombinant nucleic acids that can be used to practice the methods are also disclosed.

Abstract: Mammalian prolactin (PRL) variants having a mutation or set of mutations within the 14 N-terminal amino acids that prevent the formation of a disulfide bridge between Cys4 and Cys11 and, a sterically hindering mutation or set of mutations within binding site 2 of PRL. These variants are useful as antagonists of mammalian prolactin receptors (PRLR), more particularly of human prolactin receptor (hPRLR).

Abstract: This application provides a process for preparing enantiomerically pure ?-D-dioxolane nucleosides. In particular, a new synthesis of (?)-DAPD, suitable for large scale development, is described. In one embodiment the invention provides a process for preparing a substantially pure ?-D- or ?-L-1,3-dioxolane nucleosides comprising a) preparing or obtaining an esterified 2,2-dialkoxy ethanol; b) cyclizing the esterified 2,2-dialkoxy ethanol with glycolic acid to obtain a 1,3-dioxolane lactone; c) resolving the 1,3-dioxolane lactone to obtain a substantially pure D- or L-lactone; d) selectively reducing and activating the D- or L-chiral lactone to obtain a substantially pure D- or L-1,3-dioxolane; e) coupling the D- or L-1,3-dioxolane to an activated and/or protected purine or pyrimidine base; and f) optionally purifying the nucleoside to obtain a substantially pure protected ?-D- or ?-L-1,3-dioxolane nucleoside.

Abstract: An isolated polynucleotide encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, with the L-aspartic acid at position 5 of the amino acid sequence replaced by another proteinogenic amino acid, and possesses citrate synthase activity. In addition, a vector comprises the polynucleotide and a bacterium comprises the vector. An isolated polynucleotide comprises a nucleotide sequence comprising, from position 1 to 39, the nucleotide sequence corresponding to position 1 to 39 of SEQ ID NO: 11, from position 40 to 105, a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 12, with each proteinogenic amino acid except L-aspartic acid being present at position 5. A method of producing an L-amino acids is also described.

Abstract: The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. Specifically, the present invention relates to expression of PUMP-1 protease (matrix metalloprotease 7). The detected proteases are themselves specifically over-expressed in certain cancers, and their presence may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment.

Abstract: The invention provides methods, reagents and kits for enabling comparative analysis of extracellular RNA species in bodily fluids including plasma and serum to detect, infer, or monitor cancer and other neoplasia.

Abstract: Provided herein are libraries of nucleic acid species each comprising a transcription unit having a promoter region operatively linked to a coding sequence. The coding sequence of each nucleic acid species encodes a RNA cleavage substrate comprising a unique compomer species and a cleavage site. Each compomer species has a molecular mass distinguishable from the molecular mass of other compomer species in the library, and cleavage at a cleavage site releases a polynucleotide comprising the compomer species from the RNA cleavage substrate.

Abstract: Compositions, methods and kits for detecting viral nucleic acids. Targets that can be detected in accordance with the invention include HBV and/or HIV-1 and/or HCV nucleic acids. Particularly described are oligonucleotides that are useful as hybridization probes and amplification primers that facilitate detection of very low levels of HBV nucleic acids.

Abstract: L-Glutamic acid is produced by culturing a microorganism in which an expression of L-glutamic acid-export gene, a yhfK gene, is enhanced or overexpressed, in a medium to produce and cause accumulation of L-glutamic acid in the medium, and collecting L-glutamic acid from the medium.

Abstract: The present invention relates to a process for producing methionine by fermentation, a process for isolating the methionine formed, the methionine-containing biomass produced in isolation, use thereof for producing a feedstuff or feed supplement, and also to the use of the isolated methionine for producing foodstuffs or feedstuffs or food supplements or feed supplements.

Abstract: The invention relates to a method for producing the optically active alkanols of formula (I), wherein n is an integer of from 0 to 5; Cyc represents an optionally substituted, mononuclear or polynuclear, saturated or unsaturated, carbocylic or heterocyclic ring, and R1 represents halogen, SH, OH, NO2, NR2R3 or NR2R3R4+X?, wherein R2, R3 and R4 independently represent H or a lower alkyl or lower alkoxy group and X? represents a counterion. According to the invention, an enzyme (E) selected from the groups of dehydrogenases, aldehyde reductases and carbonyl reductases is incubated in a medium containing the alkanone of formula (II), wherein n, Cyc and R1 are defined as above, in the presence of reduction equivalents.

Abstract: The present invention relates to applications of far-infrared-inducing natural minerals to improve biomass conversion performance by promoting the growth of microbes, especially in the fermentation process. The present invention further relates to the enhancement of other enzyme reactions during the fermentation process. The present invention is applicable for use in corn-to-ethanol fermentation to increase the ethanol productivity as well as for yeast manufacturing.

Abstract: The present invention relates to novel amino acid and nucleic acid sequences of cyclic nucleotide-specific phosphodiesterases from the parasite Leishmania major. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the amino acid and nucleic acid sequences. The invention further relates to the use of these sequences, and of antibodies directed against these sequences, in the diagnosis and treatment of disorders related to the infection of Leishmania major, including the identification of compounds that form complexes with the polypeptides and nucleic acids of the present invention.

Abstract: The present invention relates to a process for heterologous expression and large-scale production of functionally active enzyme trypanothione reductase of Leishmania donovani in prokaryotic system.

Abstract: A mutant protein having diaphorase activity is provided. A mutant protein includes an amino acid sequence obtained by deletion, replacement, addition, or insertion of at least one amino acid residue of a native-form amino acid sequence of SEQ. ID. No. 1, wherein the mutant protein has diaphorase activity with an enzyme activity of 245 or more.

Abstract: The present invention relates to means for cleaving a nucleic acid cleavage structure in a site-specific manner. Enzymes, including 5? nucleases and 3? exonucleases, are used to detect and identify nucleic acids derived from microorganisms. Methods are provided which allow for the detection and identification of bacterial and viral pathogens in a sample.

Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.

Abstract: A modified Family 6 cellulase enzyme comprising a proline residue at position 413 is provided. Genetic constructs and genetically modified microbes comprising DNA sequences encoding the modified Family 6 cellulase are also provided. Family 6 cellulases of the invention display improved thermostability, thermophilicity, alkalophilicity, or a combination thereof, relative to the parent Family 6 cellulases. Such cellulases find use in a variety of applications in industry that require cellulase stability and activities at temperatures, pH values, or both, above that of the native enzyme.

Abstract: The invention relates to nucleic acids encoding polypeptides having amylase activity, and methods for making and using them. In one aspect, the polypeptides having amylase activity have increased activity and stability at acidic, neutral and alkaline pH and increased temperature. In one aspect, the invention provides methods for producing an alcohol, for producing a high-maltose or a high-glucose syrup or a mixed syrup, for liquifying a starch-comprising composition, comprising use of polypeptides encoded by the nucleic acids of this invention.

Abstract: Targeted acid alpha-glucosidase therapeutics that localize to the lysosome are provided. The targeted therapeutics include a therapeutic agent, GAA, and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.

Abstract: This invention relates to a novel form of protein C or activated protein C. More specifically, the invention is directed to a variant of protein C that is activated at a higher rate than wild-type or other variants and produces an activated protein C with reduced anticoagulant properties while retaining the protective anti-inflammatory and anti-apoptotic properties of wild-type activated protein C. This novel APC variant will be beneficial for treating inflammatory and apoptotic disorders with a reduced risk for bleeding.

Abstract: The present invention provides a bacterium which has an ability to produce a useful metabolite derived from acetyl-coenzyme A, such as L-glutamic acid, L-glutamine, L-proline, L-arginine, L-leucine, L-cysteine, succinate, and polyhydroxybutyrate, wherein said bacterium is modified so that activities of D-xylulose-5-phosphate phosphoketolase and/or fructose-6-phosphate phosphoketolase are enhanced. The present invention also provides a method for producing the useful metabolite using the bacterium.

Abstract: The present invention relates to methods for displaying (poly)peptides/proteins on the surface of bacteriophage particles by attaching the (poly)peptide/proteins via disulfide bonds.

Abstract: A method is provided for producing L-histidine using bacterium of the Enterobacteriaceae family wherein the L-amino acid productivity of said bacterium is enhanced by enhancing an activity of the AICAR transformylase-IMP cyclohydrolase encoded by the purH gene.

Abstract: The present disclosure identifies pathways and mechanisms to confer improved industrial fitness on engineered organisms. It also discloses engineered organisms having improved industrial fitness. Synthetic biologic engineering modules are disclosed that provide for light capture, carbon dioxide fixation, NADH production, NADPH production, thermotolerance, pH tolerance, flue gas tolerance, salt tolerance, nutrient independence and near infrared absorbance. The disclosed engineered organisms can include one or more of these modules. Also provided are methods of using the engineered organism to produce carbon-based products of interest, biomass or pharmaceutical agents.

Abstract: The invention relates to a thin film coated array and the process of fabricating and using the array including methods of etching, depositing a thin film coating, preparing and using the thin film coated array.

Abstract: An apparatus and method for catalyzing a reaction on a substrate (24) comprising, a light source (12), a micromirror (16) positioned to redirect light (14) from the light source (12) toward a substrate (24) wherein the redirected light (14) catalyzes a chemical reaction proximate a substrate (24), is disclosed. A computer (18) is connected to, and controls, the positioning of mirrors within the micromirror (16) to specifically redirect light to specific portions of a substrate. The substrate (24) can be placed in a reaction chamber (50), wherein the light (14) that is redirected by the micromirror (16) catalyzes a chemical reaction proximate a substrate (24).